Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 6/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389572 | 0.89 | GPR119 (0.58) | GPR119CYP2C9 | |
| SCHEMBL1837819 | 0.76 | KDM5B (0.41) | GPR119FLT3CDK2CDK6MEN1 | |
| SCHEMBL5188992 | 0.76 | GPR119 (0.45) | GPR119FLT3CDK2CDK6CYP2C9 | |
| SCHEMBL5048764 | 0.75 | GPR119 (0.49) | GPR119FLT3CDK2CDK6 | |
| SCHEMBL390523 | 0.74 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL13685341 | 0.73 | GPR119 (0.53) | GPR119FLT3CDK2CDK6CYP2C9 | |
| SCHEMBL1830976 | 0.72 | GPR119 (0.45) | GPR119FLT3CDK2CDK6MEN1 | |
| SCHEMBL5264014 | 0.72 | GPR119 (0.46) | GPR119FLT3CDK2CDK6 | |
| SCHEMBL1070555 | 0.71 | GPR119 (0.47) | GPR119FLT3CDK2CDK6CYP2C9 | |
| SCHEMBL5046848 | 0.71 | GPR119 (0.44) | GPR119FLT3CDK2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322157-A1 | Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322150-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322152-A1 | Method of preparing a composition comprising a GPR119 agonist | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322151-A2 | Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322156-A1 | Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2116235-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1808168-B1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1758565-B1 | Method of identifying GLP-1 secretagogues | ARENA PHARM INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1997484-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |